Journal of the American Academy of Child & Adolescent Psychiatry
AACAP Official ActionPractice Parameter on the Use of Psychotropic Medication in Children and Adolescents
Section snippets
Methodology
A literature review of relevant articles pertaining to psychopharmacology in children and adults was completed using the PubMed database. In addition, textbooks on pediatric psychopharmacology were reviewed as were their reference lists. In addition, a PubMed search on quality medical care and the overuse of medical testing (e.g., routine laboratory or radiological testing), other medical procedures considered to be used excessively (e.g., cesarean section), and other medical conditions that
General Background
The increased use of psychotropic medications3, 4 and psychotropic medication combinations14, 15 to treat childhood psychiatric disorders reflects a deservedly larger role for medication treatment of childhood psychiatric disorders. A number of factors have likely influenced this increased use including increased support for the biological basis of some childhood psychiatric disorders, a developing evidence base demonstrating the efficacy of psychotropic medications in children and adolescents,
Assessment
Principle 1. Before Initiating Pharmacotherapy, a Psychiatric Evaluation Is Completed. The psychiatric evaluation7 is comprehensive enough to identify symptoms best addressed pharmacologically and best addressed with psychosocial treatments and to identify psychosocial factors that may impede an adequate and safe medication trial or confound the assessment of outcome. A comprehensive evaluation increases the likelihood that medication interventions will be well conceptualized and hopefully
Parameter Limitations
The AACAP practice parameters are developed to assist clinicians in psychiatric decision making. These parameters are not intended to define the standard of care, nor should they be deemed inclusive of all proper methods of care or exclusive of other methods of care directed at obtaining the desired results. The ultimate judgment regarding the care of a particular patient must be made by the clinician in light of all of the circumstances presented by the patient and his or her family, the
References (65)
- et al.
National trends in the use of psychotropic medications by children
J Am Acad Child Adolesc Psychiatry
(2002) - et al.
Clomipramine hydro-chloride in childhood and adolescent obsessive-compulsive disorder–a multicenter trial
J Am Acad Child Adolesc Psychiatry
(1992) - et al.
Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial
JAm Acad Child Adolesc Psychiatry
(2004) - et al.
Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
Fluoxetine for the treatment of childhood anxiety disorders
J Am Acad Child Adolesc Psychiatry
(2003) - et al.
A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder
Biol Psychiatry
(2007) - et al.
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II
J Am Acad Child Adolesc Psychiatry
(2003) - et al.
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review
J Am Acad Child Adolesc Psychiatry
(2003) - et al.
Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder
JAm Acad Child Adolesc Psychiatry
(2001)
Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders
J Am Acad Child Adolesc Psychiatry
Treatment-resistant depression in adolescents: recognition and management
Child Adolesc Psychiatr Clin N Am
Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology
J Am Acad Child Adolesc Psychiatry
Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment
J Am Acad Child Adolesc Psychiatry
Phenomenology of tics and natural history of tic disorders
Brain Dev
Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS)
J Am Acad Child Adolesc Psychiatry
Combination lithium and divalproex sodium in pediatric bipolarity
J Am Acad Child Adolesc Psychiatry
Youth psychotherapy outcome research: a review and critique of the evidence base
Annu Rev Psychol
Office of the Surgeon General. Report of the Surgeon General's conference on children's mental health: a national action agenda
Psychotropic practice patterns for youth: a 10-year perspective
Arch Pediatr Adolesc Med
New data show declines in antidepressant prescribing
Psychiatr News
Annual summary of vital statistics: 2005
Pediatrics
Practice parameters for the psychiatric assessment of children and adolescents
J Am Acad Child Adolesc Psychiatry
Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder
J Am Acad Child Adolesc Psychiatry
Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder
J Am Acad Child Adolesc Psychiatry
Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders
J Am Acad Child Adolesc Psychiatry
Practice parameter for the assessment and treatment of children and adolescents with depressive disorders
J Am Acad Child Adolesc Psychiatry
Practice parameter for the assessment and treatment of children and adolescents with schizophrenia
J Am Acad Child Adolesc Psychiatry
Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder
J Am Acad Child Adolesc Psychiatry
Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder
Pediatrics
Multiple psychotropic pharmacotherapy among children and adolescent enrollees in Connecticut Medicaid managed care
Psychiatr Serv
Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers
J Dev Behav Pediatr
Cited by (0)
This parameter was developed by John Walkup, M.D., principal author, and the Work Group on Quality Issues: William Bernet, M.D., Oscar Bukstein, M.D., M.P.H., and Heather Walter, M.D., M.P.H., Co-Chairs, and Valerie Arnold, M.D., R. Scott Benson, M.D., Joseph Beitchman, M.D., Allan Chrisman, M.D., Tiffany R. Farchione, M.D., John Hamilton, M.D., Helene Keable, M.D., Joan Kinlan, M.D., Jon McClellan, M.D., Ulrich Schoettle, M.D., Jon Shaw, M.D., Matthew Siegel, M.D., and Saundra Stock, M.D. American Academy of Child and Adolescent Psychiatry (AACAP) Staff: Kristin Kroeger Ptakowski and Jennifer Medicus.
AACAP practice parameters are developed by the AACAP Work Group on Quality Issues (WGQI) in accordance with American Medical Association policy. Parameter development is an iterative process between the primary author(s), the WGQI, topic experts, and representatives from multiple constituent groups, including the AACAP membership, relevant AACAP components, the AACAP Assembly of Regional Organizations, and the AACAP Council. Details of the parameter development process can be accessed on the AACAP Web site. Responsibility for parameter content and review rests with the author(s), the WGQI, the WGQI Consensus Group, and the AACAP Council.
The AACAP develops both patient-oriented and clinician-oriented practice parameters. Patient-oriented parameters provide recommendations to guide clinicians toward best treatment practices. Recommendations are based on empirical evidence (when available) and clinical consensus (when not) and are graded according to the strength of the empirical and clinical support. Clinician-oriented parameters provide clinicians with the information (stated as principles) needed to develop practice-based skills. Although empirical evidence may be available to support certain principles, principles are primarily based on expert opinion derived from clinical experience. This parameter is a clinician-oriented parameter.
The primary intended audience for the AACAP practice parameters is child and adolescent psychiatrists; however, the information contained therein may also be useful for other mental health clinicians. The author acknowledges the following experts for their contributions to this parameter: Daniel S. Pine, M.D., Laurence L. Greenhill, M.D., Christopher Kratochvil, M.D., Aradhana Bela Sood, M.D., Mark Riddle, M.D., Timothy Wilens, M.D., and Charles H. Zeanah, Jr., M.D. This parameter was reviewed at the Member Forum at the AACAP Annual Meeting in October 2005.
From September 2006 to December 2007, this parameter was reviewed by a Consensus Group convened by the WGQI. Consensus Group members and their constituent groups were as follows: WGQI (Oscar Bukstein, M.D., Chair, Allan Chrisman, M.D., and Saundra Stock, M.D., Members); Topic Experts (Daniel S. Pine, M.D., and Timothy Wilens, M.D.); AACAP Assembly of Regional Organizations (Susan Daily, M.D.); and AACAP Council (Aradhana Bela Sood, M.D., and Charles Zeanah, Jr., M.D.).
Disclosures of potential conflicts of interest for authors and WGQI chairs are provided at the end of the parameter. Disclosures of potential conflicts of interest for all other individuals named above are provided on the AACAP Web site on the Practice Information page.
This practice parameter was approved by the AACAP Council on March 18, 2009. This practice parameter is available on the Internet (www.aacap.org). Reprint requests to the AACAP Communications Department, 3615 Wisconsin Avenue, NW, Washington, DC 20016.